Should I buy Progyny (PGNY) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Progyny
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| JP Morgan | 57 % | +6.2 % | 7 | $30 +16% |
| Barclays | 20 % | +1.2 % | 5 | $30 +16% |
| Cantor Fitzgerald | 50 % | -0.9 % | 10 | $28 +8% |
| Truist Securities | 25 % | -18.3 % | 8 | $36 +39% |
| Keybanc | 20 % | -23.0 % | 5 | $35 +35% |
| SVB Leerink | 67 % | +50.2 % | 6 | — |
✅ Reasons to believe
- 78% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.
- Median price target $35, i.e. +35% from the current price ($26).
- The most reliable firm on PGNY, JP Morgan (57% hit rate, 7 scored calls), targets $30 (call made on August 21, 2026, maturing on August 21, 2027) (+16%) in its most recent call, and $26 (call made on November 11, 2025, maturing on November 11, 2026) (+1%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 9 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on PGNY
Median target $35 (+35%) · 9 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Progyny now?
We won't decide for you. The facts: 78% of analysts rate it a buy, median target $35 (+35%), and JP Morgan (most reliable on PGNY, 57%) targets $30. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Progyny?
Not according to analysts: the median target ($35) is still +35% above the current price ($26) (most reliable on PGNY: JP Morgan, 57%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Progyny still worth investing in?
It depends on the gap between the price ($26) and its estimated value: analysts target $35 on median (+35%), with 78% buys (most reliable on PGNY: JP Morgan, 57%). Cross-check with their real reliability on PGNY and the cautions above. Information, not advice.
What's the main risk in buying PGNY?
The consensus is not unanimous: of 9 ratings, 2 are neutral.
→ Go deeper: the full Progyny profile (consensus, analyst reliability, price target, performance).